Currently Viewing:
Newsroom
Currently Reading
Aetna to Cover Prosigna Gene Signature Assay for Breast Cancer
May 09, 2016 – AJMC Staff
What We're Reading: Arizona Revives Its Children's Health Insurance Program
May 09, 2016 – AJMC Staff
Motivational Interviews Reduce Risky Opioid Use
May 08, 2016 – Jackie Syrop
Researchers Discover New Mechanism Related to Heart Failure
May 07, 2016 – Brenna Diaz
This Week in Managed Care: May 7, 2016
May 07, 2016
Newer Insulins May Increase Pharmacy Expenses but Reduce ED Visits
May 07, 2016 – Priyam Vora
ICER's HTA Report for Multiple Myeloma: New Drugs Clinically Promising, Cost Effectiveness Unclear
May 06, 2016 – Surabhi Dangi-Garimella, PhD
What We're Reading: Republicans, Democrats Unite Against Medicare Part B Proposal
May 06, 2016 – AJMC Staff
FDA Extends Authority Over E-Cigarettes, Receives ASCO's Praise
May 05, 2016 – Surabhi Dangi-Garimella, PhD

Aetna to Cover Prosigna Gene Signature Assay for Breast Cancer

AJMC Staff
Nanostring Technologies has announced that its Prosigna Breast Cancer Gene Signature Assay has received a positive coverage decision from the commercial health plan Aetna.
Nanostring Technologies, a manufacturer of molecular diagnostic tests, has announced that its Prosigna Breast Cancer Gene Signature Assay has received a positive coverage decision from the commercial health plan Aetna.

Prosigna, based on the PAM50 gene signature, was deemed medically necessary by the American Society of Clinical Oncology earlier this year, to assess the need for adjuvant chemotherapy in ER-positive, HER2-negative, node-negative breast cancer.

“Aetna is one of the nation’s largest health plans, and its decision to cover Prosigna is a clear sign of the expanded interest we are garnering from public and private payors alike,” said Brad Gray, president and CEO of NanoString Technologies, in a statement. “Our team at NanoString will continue to work with national and regional payors to ensure their patients have access to this vital test. We estimate that approximately 80% of patients indicated for Prosigna testing are now covered.”

The Prosigna assay, which faces competition from both MammaPrint (by Agendia) and Oncotype DX (by Genomic Health), is a decentralized test, which allows faster turnaround time as well as easier access. The test is indicated in female breast cancer patients who have undergone surgery in conjunction with locoregional treatment consistent with standard of care.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up